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An antiserum to pure glutamate decarboxylase (CGAD) when incubated with rat cortical synaptosomes 
in the presence of complement caused release of 33-53% of lactate dehydrogenase (LDH) and 22-41% 
of total GAD. In addition most of the y-aminobutyrate (GABA) present was released. Anti-GAD an- 
tiserum alone, or complement alone, were without action. The antiserum plus complement had no effect 
on noradrenaline or choline uptake, and did not release cholineacetylase (ChAT). Anti-ChAT serum plus 
complement released 30-37070 of ChAT and lo-13% of LDH. It prevented choline uptake. This serum 
did not produce GAD release or prevent GABA, choline or noradrenaline uptake. When cortical synap- 
tosomes were exposed to both antisera plus complement, their actions were strictly additive. The data in- 
dicate specific lysis of GABAergic and cholinergic synaptosomal sub-populations. 
Synaptosome GABAergic Lysis 
1, INTRODUCTION 
A major limitation in the use of synaptosomes 
from mammalian brain in the study of synaptic 
biochemistry is the heterogeneity of the prepara- 
tions. Neurones which employ different neuro- 
transmitters each contribute their nerve-terminals 
to the preparations obtained by density-gradient 
centrifugation [ 11. Antisera directed against 
specific components of these neurotransmitter 
systems could theoretically be used to achieve a 
separation of these sub-populations of synap- 
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tosomes, if the relevant specific antigens were 
located on the outer face of the synaptosomal 
membrane. Such techniques have been applied to 
the separation of lymphocytes [2]. 
We recently reported that an antiserum to a 
choline acetyltransferase preparation allowed 
complement-mediated lysis of the cholinergic sub- 
population of cortical synaptosomes [3]. We now 
describe a similar effect produced by an antiserum 
to glutamate decarboxylase, purified from mouse 
brain. This preparation, in the presence of comple- 
ment, appears to lyse GABAergic synaptosomes, 
whilst having no action on either the cholinergic or 
the noradrenergic sub-populations. 
2. METHODS 
Antibodies against purified GAD from mouse 
brain were produced in rabbits by bi-weekly injec- 
tions of a total of 50-60,ug of protein over a 
period of 8 weeks. Antisera obtained were charac- 
terized by immunodiffusion, enzyme inhibition, 
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immunoelectrophoresis and microcomplement fix- 
ation test [4-61. 
Antibodies against ChAT were prepared as in 
[3]. GAD activity in synaptosome preparations 
was assayed by the production of i4C02 from L- 
[U-‘4C] glutamic acid (280 mCi/mmoI, Amer- 
sham). Incubations of I-ml volumes were perform- 
ed in glass scintillation vials sealed with rubber 
suba-seals (no.33), and contained 25 mM 
glutamate, 1 mM dithiothreitol, 0.2 mM pyridoxal 
phosphate, 1 mg/ml BSA in 50 mM sodium 
phosphate buffer (pH 6.8). An Eppendorf tube, 
with cap removed, was placed in each scintillation 
vial and contained 20 ~120% NaOH absorbed in a 
small strip of filter paper. The reaction was started 
by placing the sealed vials into a shaking water 
bath at 37°C. After 30 min, 50~1 of ION H2S04 
was injected through the suba-seal and into the in- 
cubation mixture to stop the reaction. The vials 
were kept at room temperature overnight to allow 
all the 14C02 released during the reaction to be 
trapped by the alkaline-soaked filter paper. The 
filter paper was then removed and placed in 10 ml 
scintillant (toluene with 0.33% w/v butyl PBD 
plus 44% v/v 2-methoxyethanol). Radioactivity 
was measured in a Packard Tri-Carb 300C liquid 
scintillation counter. Blank values (l-5%) ob- 
tained by incubating 14C-glutamate in the absence 
of synaptosome preparations were subtracted from 
sample values. 
The sodium-dependent uptake of [methyl-3H] 
choline chloride (15 Ci/mmol, Amersham) at 
0.0625-2 PM choline, and of 4-amino-n-[2,3-3H] 
butyric acid (64 Ci/mmol, Amersham) at 
0.125-4 PM, into rat cerebrocortical synap- 
tosomes [7] was measured as in [3]. The sodium- 
dependent uptake of DL-[7-3H] noradrenaline 
hydrochloride (13 Ci/mmol, New England 
Nuclear) at 0.0625-2 ,uM was measured in a 
similar manner, in the presence of ascorbic acid 
(0.1 mg/ml) and nialamide (10 PM). Uptake of 
DL-[7-3H] noradrenaline and [methyl-3H] choline 
chloride was also assayed in synaptosomes that 
had been hypotonically lysed in 8 mM Tris-HCl 
(pH 8.1) at a protein concentration of 1 mg/lO ml 
for 30 min at 0-4°C. Synaptosomes were pelleted 
at 10000 x g and resuspended in 0.32 M sucrose at 
a protein concentration of 2 mg/ml. In some ex- 
periments synaptosomes were pre-incubated with 
Krebs incubation medium containing 1 PM 
58 
dopamine prior to the assay of NA uptake. 
Choline acetyltransferase activity was measured 
using 0.4 mM [l-i4C] acetyl coenzyme A 
(4 mCi/mmol, Amersham) as in [8] using incuba- 
tion volumes of 35 ~1. Lactate dehydrogenase ac- 
tivity was measured as in [9]. Samples were 
prepared for amino acid analysis as in [IO]. 
The actions of the antisera were tested by in- 
cubating cortical synaptosomes (400 pug pro- 
tein/ml) in 500 pl of Krebs-Ringer phosphate 
which contained either GAD antiserum (50 or 
100 ~1) or ChAT antiserum (100 ~1) plus 50 ,J of 
guinea pig complement (Gibco Labs), or the an- 
tisera alone for 30 min at 37°C (maximal effects 
were measured after 30 min incubation). In some 
experiments synaptosomes were incubated with 
both anti-GAD (50 ,ul) and anti-ChAT (100 ~1) sera 
in the presence of complement (50~1). After in- 
cubation, the synaptosomes were deposited by cen- 
trifugation at 10000 x g. The supernatant was re- 
tained for the measurement of GAD, ChAT and 
LDH activity and GABA. The pellets were first 
washed with sodium free Krebs-Ringer medium 
before being resuspended in 0.32 M sucrose (2 mg 
synaptosomal protein/ml) for the assay of choline, 
GABA and NA uptake, where 25 ~1 of this suspen- 
sion was added to 250 ~1 final incubation volume. 
ChAT and LDH activity in the pellets was 
measured after resuspension in 1% Triton X-100 
(v/v). The activity of GAD in the pellets was 
assayed after lysis produced by resuspension in 
8 mM Tris-HCl (pH 8.1) and freezing and thaw- 
ing, twice. 
3. RESULTS AND DISCUSSION 
The results of table 1 show that the anti-GAD 
serum released 58-68% of synaptosomal GAD at 
a dilution of 1: 10 in the incubation medium, pro- 
vided complement was added. Increasing the con- 
centration of this antiserum 2-fold did not increase 
the extent of the GAD release. Under these condi- 
tions (1: 10 dilution) GABA was also found to be 
released into the supernatant hough no GABA 
was detectable in the absence of complement. The 
enzyme ChAT was not released by the anti-GAD 
serum (+- complement). 
Measurement of LDH showed that this soluble 
enzyme was released into the incubation medium 
to the extent of 43-58% by this antiserum at the 
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Table 1 
Effects of antisera on release from cerebrocortical synaptosomes prepared from rat 
February 1983 
Treatment GAD activity GABA release ChAT activity LDH activity 
(% released) ((r/o released) (070 released) 
Krebs medium 
Control serum (1 : 5) + 
complement 
Anti-GAD serum (1: 10) + 
complement 
Anti-GAD serum (1: 5) + 
complement 
Anti-GAD serum (1 : 10) 
Anti-GAD serum (1: 5) 
Complement 
Anti-ChAT serum (1: 5) + 
complement 
Anti-ChAT serum (1: 5) + 
Anti-GAD serum (1: 10) t 
complement 
n.d. 
n.d. 
58-68 
49-66 
n.d. 
n.d. 
14-21 
n.d. 
45-60 
n.d. 
n.m. 
158 ? 20 
n.m. 
n.d. 
n.m. 
n.d. 
n.m. 
n.m. 
n.d. 
5- 6 
n.d. 
n.d. 40-60 
n.d. 4- 7 
n.d. 3- 6 
n.d. 4- 6 
36-43 
29-39 
5- 7 
6- 8 
43-58 
17-20 
62-79 
Values given are means + SD. from at least 4 separate synaptosome preparations and are calculated 
after subtraction of that free in the medium at the start of each incubation. Values for GABA release 
are in units of pmol/20 pg synaptosomal protein/30 min. Total activities/mg synaptosomal protein 
were: GAD, 200 + 60 pmol CO2 .min-‘; ChAT, 360 f 27 pmol ACh. min-’ and LDH, 1.8 + 
0.16~mol.min-’ 
n.d., not detectable; n.m., not measured 
Table 2 
Effect of antiserum to purified GAD on uptake into cerebrocortical synaptosomes prepared from rat 
Treatment Sodium-dependent 
choline uptake 
V max Kill 
Sodium-dependent 
GABA uptake 
V max Km 
Sodium-dependent 
uptake of 
0.0625 PM NA 
Krebs medium 50 * 6 0.52 k 0.05 760 + 69 4.8 + 0.4 14.2 
Anti-GAD serum (1: 10) + 
complement 53 2 6 0.51 + 0.06 782 + 80 4.4 ? 0.5 13.8 
Anti-ChAT serum (1: 5) + 
complement n.d. n.d. 680 f 80 5.4 + 0.7 15.2 
Values given for choline and GABA uptake are means + S.D. from at least 4 separate synaptosome preparations. NA 
uptake values are from 2 preparations and are in units of pmol . mg synaptosomal protein-‘. 2 min-‘. Vmax values for 
choline and GABA uptake are given in the same units. K, is given in units of PM. n.d., not detectable 
1: 10 dilution, and by 40-60% at the 1:5 dilution, 
provided complement was present. Neither com- 
plement alone, nor antiserum alone caused any 
release of LDH, ChAT or of GABA above control 
levels. Complement itself contained GAD activity 
(43 f 9 pmol CO2 . min-’ .50 pl-‘, n = 6) and this 
fully accounts for the apparent releasing action of 
complement shown in table 1. The GAD antiserum 
was without action on either choline or 
noradrenaline uptake (table 2). 
59 
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These results indicate that this antiserum con- 
tains antibodies capable of lysing about half of the 
cortical synaptosomes, whilst releasing both GAD 
and GABA. The lack of action on choline or on 
noradrenaline uptake (table 2), and the absence of 
any ChAT release (table 1) suggests that there is a 
considerable degree of specificity with regard to 
the sub-population(s) which is vulnerable to lysis 
by the GAD antiserum plus complement, and 
strongly indicates that it may well be confined to 
the GABAergic terminals. 
Dopamine (1 PM) blocks noradrenergic uptake 
by cerebrocortical synaptosomes (fig. l), and 
hypotonic lysis greatly reduced both noradrenaline 
and choline uptake (fig.2), indicating that the 
usual form of sodium-dependent high affinity up- 
take was being measured. Uptake measured under 
these conditions (fig.2) no longer conformed to 
Michaelis-Menten kinetics (choline uptake; r = 
- 0.66, y = 10 - 1.68x), noradrenaline uptake; r = 
-0.66, y = 20-2.5x). 
When both anti-GAD and anti-ChAT sera were 
added to cerebrocortical synaptosome prepara- 
tions together with complement, the total LDH 
release observed (62-7970) was equivalent to the 
sum of the actions of each antiserum when added 
alone (table 1). ChAT antiserum, whilst releasing 
ChAT, was without effect on either GAD or 
GABA, and did not influence NA uptake. 
V 
Fig. 1. Typical Eadie-Hofstee plots of sodium-dependent 
choline (O---O) and noradrenaline (M) uptake into 
control synaptosomes. Noradrenaline uptake into syn- 
aptosomes in the presence of 1 PM dopamine is also 
shown (A---A). Data are the means of triplicate 
determinations at each substrate concentration. Lines 
through the points were determined using linear 
regression analysis. 
If the anti-GAD serum is acting specifically on 
GABAergic terminals, the lack of effect on GABA 
uptake (table 2) has to be satisfactorily explained, 
especially as the antiserum appears to release 
GABA itself (table 1). The GABA uptake 
measured in our system has been shown to be 
reduced by hypotonic lysis of synaptosomes, and is 
blocked by DABA [3], indicating that it is the stan- 
dard form of sodium-dependent high-affinity 
GABA uptake. The most likely explanation is that 
GABA is taken up by structures other than 
GABAergic terminals, such as free mitochondria 
which can employ GABA as an effective metabolic 
substrate [111. 
The results reported here and previously [3] on 
the extent of LDH release by either GAD an- 
tiserum or by ChAT antiserum indicate that the 
contribution of GABAergic terminals to rat cor- 
tical synaptosome preparations is about 40%, 
whilst cholinergic terminals contribute about 10%. 
This is confirmed by the strictly additive effect of 
exposing synaptosomes to both antisera 
simultaneously. The additive nature of these ac- 
tions, and the change in specific properties (e.g., 
choline uptake loss, GAD release) effected by each 
antiserum makes it most unlikely that the location 
of GAD and of ChAT in the outer synaptosomal 
membrane is an artefact due to surface adsorption 
during synaptosome preparation. The surface 
V 
Fig.2. Typical Eadie-Hofstee plots of sodium-dependent 
choline (+-o) and noradrenaline (H) uptake into 
lysed synaptosomes. Data calculated as in fig.1. 
60 
Volume 152, number 1 FEBS LETTERS February 1983 
localization of specific markers of this kind for 
each neuronal type would be of great value in 
directing growing nerve-fibres to their target sites 
during brain development, even though the bulk of 
the enzyme is located elsewhere (e.g., in the 
cytoplasm). 
It is possible that neurotransmitter synthesising 
enzymes may be expressed on the surface of 
neurones employing other neurotransmitters, and 
we are currently investigating whether or not this 
is a general rule. 
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